Phase I study with ONCOS-102 for the treatment of solid tumors ᾿an evaluation of clinical response and exploratory analyses of immune markers
详细信息 查看全文
- 作者：Tuuli Ranki ; Sari Pesonen ; Akseli Hemminki…
- 关键词：Immunotherapy ; in situ vaccine ; Cytotoxic CD8+ T cell ; Anti ; tumor immunity ; Intratumoral ; Oncolytic adenovirus
- 刊名：Journal for Immunotherapy of Cancer
- 出版年：2016
- 出版时间：December 2016
- 年：2016
- 卷：4
- 期：1
- 全文大小：1,818 KB
- 刊物主题：Oncology;
- 出版者：BioMed Central
- ISSN：2051-1426
文摘
Background We conducted a phase I study with a granulocyte macrophage colony stimulating factor (GMCSF)-expressing oncolytic adenovirus, ONCOS-102, in patients with solid tumors refractory to available treatments. The objectives of the study were to determine the optimal dose for further use and to assess the safety, tolerability and adverse event (AE) profile of ONCOS-102. Further, the response rate and overall survival were evaluated as well as preliminary evidence of disease control. As an exploratory endpoint, the effect of ONCOS 102 on biological correlates was examined.